Introduction
Methods
Stage 1 translation of MFPDI and translational equivalence testing, pilot testing and content validity testing of the C-MFPDI
Stage 2 psychometric properties testing of the C-MFPDI
Statistical analysis
Results
Stage 1: Translational equivalence testing, pilot testing and content validity testing results
Stage 2 psychometric properties testing results
Demographic and clinical characteristics | Mean (SD) | n (%) |
---|---|---|
Female | 67 (67%) | |
Age (Years) | 52.9 (14.7) | |
Educational level | ||
Tertiary (‘A’ levels, Diploma, Degree) | 41 (41%) | |
Employment status | ||
Full-time | 44 (44%) | |
Retired | 20 (20%) | |
Part time/ Schooling/Homemaker | 26 (26%) | |
Unemployed due to IA symptoms/other reasons | 10 (10%) | |
Diagnosis and duration since diagnosis | 7.9 (8.6) | |
Rheumatoid arthritis | 8.6 (8.9) | 70 (70%) |
Psoriatic arthritis | 5.8 (5.8) | 5 (5%) |
Spondyloarthritis | 12.2 (12.6) | 17 (17%) |
Undifferentiated inflammatory arthritis | 7.7 (8.6) | 8 (8%) |
IA symptoms impacted daily activities (Yes) | 71 (71%) | |
IA symptoms impacted social activities (Yes) | 28 (28%) | |
IA symptoms impacted work ability (Yes) | 32 (32%) | |
Ever visited podiatrist (Yes) | 29 (29%) | |
Use of assistive device for walking (Yes) | 22 (22%) | |
Tender joint count (28) | 2.6 (4.4) | |
Swollen joint count (28) | 1.0 (2.4) | |
DAS28-ESRb score (n = 74) | 3.4 (1.1) | |
DAS28-CRPb score (n = 24) | 3.0 (0.9) | |
DAS28-ESRb score ranking (n = 74) | ||
Disease in remission (DAS28 < 2.6) | 17 (23%) | |
Low disease activity (DAS28 > 2.6 but</=3.2) | 24 (32%) | |
Moderate Disease activity (DAS28 > 3.2 but< 5.1) | 28 (38%) | |
Active disease (DAS28 > 5.1) | 5 (7%) |
Outcomes | Mean (SD) | Actual range | Possible range |
---|---|---|---|
VASa for foot pain (today) | 1.6 (2.3) | 0–8 | 0–10 |
VAS for foot pain (month) | 2.9 (2.6) | 0–8 | 0–10 |
Taiwan Chinese FFIb pain | 1.8 (2.1) | 0–8 | 0–10 |
Taiwan Chinese FFI disability | 1.9 (2.4) | 0–9.7 | 0–10 |
Taiwan Chinese FFI activity limitation | 1.4 (2.1) | 0–8.7 | 0–10 |
C-MFPDIc pain intensity | 2.0 (2.3) | 0–8 | 0–10 |
C-MFPDI personal appearance | 1.3 (1.5) | 0–4 | 0–4 |
C-MFPDI functional limitation | 4.6 (5.1) | 0–20 | 0–20 |
C-MFPDI total score | 7.8 (7.5) | 0–30 | 0–34 |
EQ-5Dd utility score | 0.7 (0.3) | −0.25 - 1.00 | − 0.77 - 1.00 |
EQ-5D global-VAS | 67.5 (17.9) | 20 - 100 | 0–100 |
Constructs | Items of the C-MFPDIa | Item-to-total correlation (n = 100) | Cronbach’s α (n = 100) | Intra-class coefficient (n = 30) |
---|---|---|---|---|
Physical limitation | 0.90 | 0.87 | ||
Item 1 | 0.67 | |||
Item 2 | 0.70 | |||
Item 3 | 0.66 | |||
Item 4 | 0.72 | |||
Item 5 | 0.71 | |||
Item 6 | 0.56 | |||
Item 7 | 0.73 | |||
Item 8 | 0.68 | |||
Item 9 | 0.59 | |||
Item 10 | 0.61 | |||
Personal appearance | 0.71 | 0.82 | ||
Item 11 | 0.55 | |||
Item 12 | 0.55 | |||
Pain intensity | 0.70 | 0.76 | ||
Item 13 | 0.47 | |||
Item 14 | 0.54 | |||
Item 15 | 0.39 | |||
Item 16 | 0.34 | |||
Item 17 | 0.59 | |||
Total score | 0.90 | 0.87 |
Correlations | 1 a | 2b | 3c | 4d | 5e | 6f | 7g | 8h | 9i | 10j | 11k |
---|---|---|---|---|---|---|---|---|---|---|---|
1. VAS (today) a | 1 | ||||||||||
2. VAS (month)b | 0.58** | 1 | |||||||||
3. C-MFPDI-FLc | 0.39** | 0.62** | 1 | ||||||||
4. C-MFPDI-PAd | 0.15** | 0.19 | 0.40** | 1 | |||||||
5. C-MFPDI-PIe | 0.65** | 0.65** | 0.68** | 0.35** | 1 | ||||||
6. C-MFPDI totalf | 0.48** | 0.65** | 0.96** | 0.57** | 0.82** | 1 | |||||
7. TW-FFI-Pg | 0.60** | 0.76** | 0.67** | 0.24* | 0.74** | 0.72** | 1 | ||||
8. TW-FFI-Dh | 0.49** | 0.63** | 0.68** | 0.21* | 0.66** | 0.70** | 0.82** | 1 | |||
9. TW-FFI -ALi | 0.37** | 0.41** | 0.61** | 0.26** | 0.54** | 0.62** | 0.60** | 0.71** | 1 | ||
10. EQ-5D utility scorej | −0.24* | −0.21* | −0.42** | −0.07 | −0.35** | −0.40** | −0.30** | −0.43** | −0.49** | 1 | |
11. EQ-5D G-VASk | −0.19 | −0.20* | −0.30** | −0.06 | −0.28** | −0.30** | −0.17 | −0.23* | −0.24* | 0.36** | 1 |